Anecortave acetate: A new approach for the medical treatment of glaucoma

The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care

Volumn , Issue , 2010, Pages 989-993

  Hennessy, Amy Lewis ^a,b   Robin, Alan L ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Ophthalmology Glaucoma   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878020052     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-76700-0_89     Document Type: Chapter

References (55)

1. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2:1031-1033.
2. Norell S. Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary openangle glaucoma. Acta Ophthalmol Suppl (Copenh). 1980;143:1-28.
3. Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol. 1980;64:134-141.
4. Norell SE, Granstrom PA, Wassen R. A medication monitor and fluorescein technique designed to study medication behaviour. Acta Ophthalmol (Copenh). 1980;58:459-467.
5. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524-530.
6. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515-523.
7. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of noncompliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477-480.
8. Kholdebarin R, Campbell RJ, Jin Y, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454-461.
9. Brown M, Brown G, Spaeth G. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol. 1984;19(1):2-5.
10. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052-5057.
11. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114:648-652.
12. Robin AL, Novack GD, Covert DW, Crockett S, Marcic T. Adherence in glaucoma: objective measurements of oncedaily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-540.
13. Robin AL, Stone JL, Sleath B, Covert DW, Cagle GD. An Objective Evaluation in Glaucoma Patients of EyeDrop Instillation Using Video Observations and Patient Surveys. Abstract presented at American Glaucoma Society Annual meeting, Washington DC, March 2008.
14. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393-398.
15. Nordstrom BL, Friedman DS, Mozafarri E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
16. Covert D, Robin AL, Novack GD. Letter to the editor. Systemic medications and glaucoma patients. Ophthalmology. 2005;112(10):1849-1850.
17. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971-976.
18. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-868.
19. Patel SC, Spaeth G. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 2005;26(3):233-236.
20. Leske MC, Heijl A, Hyman L, et al. Predictors of longterm progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-1972.
21. Urquhart J. The drugs not taken. Science. 2008;321(5890):769.
22. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patientreported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431-436.
23. Tsai T, Robin AL, Smith JP. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29-35.
24. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836-837.
25. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: oneyear randomized trial. Arch Ophthalmol. 2002;120:915-922.
26. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893-899.
27. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990;97:1423-1427.
28. Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):9-12.
29. Augustin A. Anecortave acetate in the treatment of agerelated macular degeneration. Clin Interv Aging. 2006;1(3):237-246.
30. Russell SR, Hudson HL, Jerdan JA, Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative agerelated macular degeneration - a review of clinical outcomes. Surv Ophthalmol. 2007;52(Suppl 1):S79-S90.
31. Clark AF, Wilson K, DeKater AW, Allingham RR, McCartney MD. Dexamethasoneinduced ocular hypertension in perfusioncultured human eyes. Invest Ophthalmol Vis Sci. 1995;36:478-489.
32. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783-793.
33. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2):275-284.
34. Robin AL, Clark AF, Covert D, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary openangle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45-50.
35. Prata TS, Tavares IM, Mello P A A, Tamura CY, Belfort R Jr. Anterior juxtascleral depot of anecortave acetate: intraocular pressure reduction in different types of glaucoma. Association for Research in Vision and Ophthalmology (ARVO); abstract 2008 E1205, poster A47.
36. Callanan D, Fuller C, Landry TA, Dickerson JE, Bergamini M V W. Prophylactic anecortave acetate in patients with a retisert implant. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 2008 E5630.
37. Landry TA, Dickerson J, Merriam JC. The use of anecortave acetate for refractory, complex glaucoma. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 1206/A48.
38. Robin AL, Suan EP, Sjaarda RN, Callanan DG, DeFaller J. Anecortave acetate lowers intraocular pressure in eyes with steroid injectionrelated glaucoma. Arch Ophthalmol. 2009;127:173-178.
39. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24-27.
40. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593-598.
41. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26(4):277-281.
42. Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late blebrelated endophthalmitis after trabeculectomy with adjunctive 5fluorouracil. Ophthalmology. 1991;98(7):1053-1060.
43. Higginbotham EJ, Stevens RK, Musch DC, et al. Blebrelated endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650-656.
44. Solomon A, Ticho U, FruchtPery J. Lateonset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. J Ocul Pharmacol Ther. 1999;15(4):283293.
45. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of lateonset blebrelated complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297-300.
46. Ashkenazi I, Melamed S, Avni I, Bartov E, Blumenthal M. Risk factors associated with late infection of filtering blebs and endophthalmitis. Ophthalmic Surg. 1991;22(10):570-574.
47. Phillips WB 2nd, Wong TP, Bergren RL, Friedberg MA, Benson WE. Late onset endophthalmitis associated with filtering blebs. Ophthalmic Surg. 1994;25(2):88-91.
48. Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma. 2000;9(6):438-443.
49. Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354-369.
50. Gottanka J, Chan D, Eichhorn M, LutjenDrecoll E, Ethier CR. Effects of TGFbeta2 in persued human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
51. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2induced changes in the human trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci. 2006;47:226-234.
52. Clark AF, Millar C, Pang IH, Jacobson N, Shepard AR. Adenoviral gene transfer of active human transforming growth factorb2 induces elevated intraocular pressure in rats. 2006 Annual Meeting Association for Research in Vision and Ophthalmology. Abstract 4771.
53. Shepard AR, Millar JC, Pang IH, Jacobson N, Clark AF. Adenoviral gene transfer of active human transforming factorb2 elevates intraocular pressure and reduces outflow facility in rodent eyes. In press.
54. Fleenor DL, Pang IH, Clark AF. Regulation of PAI1 protein in human trabecular meshwork cells. 2008 Annual Meeting Association for Research in Vision and Ophthalmology (ARVO), Abstract 1631.
55. Distelhorst JS, Hughes GM. Openangle glaucoma. Am Fam Physician. 2003;67(9):1937-1944.